⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Open Access

Evaluation of a stabilizing agent in messenger RNA vaccines for logistical application in Brazil

Tamires Pereira Ingrid Correia Ana Frederico Ester Barreto Felipe Coelho Nina Barreira Raysa Souza Juliana Melgaço Patrícia Neves Ana Bom

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness of a stabilizing agent in messenger RNA vaccines for improved logistical application in Brazil.
Evaluation of a stabilizing agent in messenger RNA vaccines.
Focus on logistical challenges in Brazil.
Coordination with Bio-Manguinhos for the symposium.
Presentation at the International Symposium on Immunobiologicals was accepted.
Findings may enhance the logistics of mRNA vaccines in Brazil.

Implication

Evaluates a stabilizing agent's effectiveness in mRNA vaccines, suggesting improved logistics for Brazil.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pereira et al. (2026) studied this question.

synapsesocial.com/papers/6a1a7ded0307b78509430cc6 https://doi.org/10.35259/isi.2026_76367

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Residual ethanol in messenger RNA vaccine: method development and routine implementationOriginal Research · 2026
2Method qualification for the assessment of mRNA vaccine encapsulation efficiencyOriginal Research · 2026
3Cellular immunological mechanisms induced by messenger RNA vaccineOriginal Research · 2026
4Analytical technology transfer for mRNA vaccine quality controlOriginal Research · 2026
5Bio-Manguinhos and new generation of vaccines: consolidation of mRNA-LNP production and evaluation of critical quality attributes at pilot scaleOriginal Research · 2026

Development and functional evaluation of conventional mRNA vaccine candidates against respiratory syncytial virus2026
Advancing the multivalent vaccine horizon: development of bicistronic self-amplifying RNA platforms for next-generation immunobiologicals2026
Integrating global vaccine trends and patent evidence to support Brazil’s domestic vaccine production capacity2026